Bioelution, Bioavailability, and Toxicity of Cobalt Compounds Correlate

Abstract Based on the wide use of cobalt substances in a range of important technologies, it has become important to predict the toxicological properties of new or lesser-studied substances as accurately as possible. We studied a group of 6 cobalt substances with inorganic ligands, which were tested for their bioaccessibility (surrogate measure of bioavailability) through in vitro bioelution in simulated gastric and intestinal fluids. Representatives of the group also underwent in vivo blood kinetics and mass balance tests, and both oral acute and repeated dose toxicity (RDT) testing. We were able to show a good correlation between high in vitro bioaccessibility with high in vivo bioavailability and subsequent high in vivo toxicity; consequently, low in vitro bioaccessibility correlated well with low in vivo bioavailability and low in vivo toxicity. In vitro bioelution in simulated gastric fluid was the most precise predictor of the difference in the oral RDT lowest observed adverse effect levels of 2 compounds representing the highly and poorly bioaccessible subset of substances. The 2 compounds cobalt dichloride hexahydrate and tricobalt tetraoxide differed by a factor of 440 in their in vitro bioaccessibility and by a factor of 310 in their RDT lowest observed adverse effect level. In summary, this set of studies shows that solubility, specifically in vitro bioelution in simulated gastric fluid, is a good, yet conservative, predictor of in vivo bioavailability and oral systemic toxicity of inorganic cobalt substances. Bioelution data are therefore an invaluable tool for grouping and read across of cobalt substances for hazard and risk assessment.

[1]  N. Lombaert,et al.  Use of Bioelution as a Screening Tool for Characterisation of Substances , 2018 .

[2]  Peter-Theodor Wilrich,et al.  Inter-laboratory validation of bioaccessibility testing for metals. , 2014, Regulatory toxicology and pharmacology : RTP.

[3]  Brent D Kerger,et al.  Refined biokinetic model for humans exposed to cobalt dietary supplements and other sources of systemic cobalt exposure. , 2014, Chemico-biological interactions.

[4]  Brooke E. Tvermoes,et al.  Effects and blood concentrations of cobalt after ingestion of 1 mg/d by human volunteers for 90 d. , 2014, The American journal of clinical nutrition.

[5]  Sharmila Baliga,et al.  Salivary pH: A diagnostic biomarker , 2013, Journal of Indian Society of Periodontology.

[6]  O. Cases,et al.  Vitamin B12 absorption: mammalian physiology and acquired and inherited disorders. , 2013, Biochimie.

[7]  D. Paustenbach,et al.  Cobalt speciation assay for human serum, Part I. Method for measuring large and small molecular cobalt and protein-binding capacity using size exclusion chromatography with inductively coupled plasma-mass spectroscopy detection , 2013 .

[8]  Brooke E. Tvermoes,et al.  Cobalt speciation assay for human serum, Part II. Method validation in a study of human volunteers ingesting cobalt(II) chloride dietary supplement for 90 days , 2013 .

[9]  D. Paustenbach,et al.  Dose-Response Relationships For Blood Cobalt Concentrations and Health Effects: A Review of the Literature and Application of a Biokinetic Model , 2012, Journal of toxicology and environmental health. Part B, Critical reviews.

[10]  A. Bansal,et al.  Augmentation of aerobic respiration and mitochondrial biogenesis in skeletal muscle by hypoxia preconditioning with cobalt chloride. , 2012, Toxicology and applied pharmacology.

[11]  Brooke E. Tvermoes,et al.  Inorganic cobalt supplementation: prediction of cobalt levels in whole blood and urine using a biokinetic model. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[12]  S. Seilkop,et al.  Oral bioaccessibility testing and read-across hazard assessment of nickel compounds. , 2012, Regulatory toxicology and pharmacology : RTP.

[13]  G. Ilavazhagan,et al.  Sub-chronic oral toxicity study in Sprague-Dawley rats with hypoxia mimetic cobalt chloride towards the development of promising neutraceutical for oxygen deprivation. , 2010, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[14]  S. Samman,et al.  Vitamin B12 in Health and Disease , 2010, Nutrients.

[15]  G. Ilavazhagan,et al.  Cobalt supplementation promotes hypoxic tolerance and facilitates acclimatization to hypobaric hypoxia in rat brain. , 2008, High altitude medicine & biology.

[16]  M. Kirchgessner,et al.  Endogenous excretion and true absorption of cobalt as affected by the oral supply of cobalt , 1994, Biological Trace Element Research.

[17]  H. Darmani,et al.  Effects of Chronic Exposure to Cobalt Chloride on the Fertility and Testes in Mice , 2008 .

[18]  M. Knöpfel,et al.  ATP-driven copper transport across the intestinal brush border membrane. , 2005, Biochemical and biophysical research communications.

[19]  J. Ashton,et al.  Comparison of the dietary cobalt intake in three different Australian diets. , 2004, Asia Pacific journal of clinical nutrition.

[20]  J. Ashton,et al.  Analysis of the cobalt content in Australian foods. , 2004, Asia Pacific journal of clinical nutrition.

[21]  W. Stopford,et al.  Bioaccessibility of metals in human health risk assessment: evaluating risk from exposure to cobalt compounds. , 2003, Journal of environmental monitoring : JEM.

[22]  W. Stopford,et al.  Bioaccessibility testing of cobalt compounds. , 2003, Journal of environmental monitoring : JEM.

[23]  D. Millhorn,et al.  Hypoxia-Inducible Factor 2α Binds to Cobalt in Vitro , 2001 .

[24]  N. Read,et al.  The effect of liquid fibre on gastric emptying in the rat and humans and the distribution of small intestinal contents in the rat. , 1993, Gut.

[25]  W. George,et al.  Histopathology of testes from mice chronically treated with cobalt. , 1992, Reproductive toxicology.

[26]  W. George,et al.  Effects of acute and chronic exposure to cobalt on male reproduction in mice. , 1988, Reproductive toxicology.

[27]  N. Read,et al.  Simultaneous measurement of gastric emptying, small bowel residence and colonic filling of a solid meal by the use of the gamma camera. , 1986, Gut.

[28]  J. Domingo,et al.  A study of the effects of cobalt administered orally to rats. , 1984, Archivos de farmacologia y toxicologia.

[29]  J. Nation,et al.  The effects of chronic cobalt exposure on behavior and metallothionein levels in the adult rat. , 1983, Neurobehavioral toxicology and teratology.

[30]  G. Speijers,et al.  Acute oral toxicity of inorganic cobalt compounds in rats. , 1982, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[31]  M. Platts,et al.  Cobalt cardiomyopathy in a patient on maintenance haemodialysis. , 1978, British medical journal.

[32]  J. R. Curtis,et al.  Possible cobalt toxicity in maintenance hemodialysis patients after treatment with cobaltous chloride: a study of blood and tissue cobalt concentrations in normal subjects and patients with terminal and renal failure. , 1976, Clinical nephrology.

[33]  C. S. Alexander.  Cobalt-beer cardiomyopathy. A clinical and pathologic study of twenty-eight cases. , 1972, The American journal of medicine.

[34]  Y. Morin,et al.  Cobalt cardiomyopathy: clinical aspects , 1971, British heart journal.

[35]  A. B. Morrison,et al.  MYOCARDIAL TOXICITY OF COBALT IN THE RAT , 1969, Annals of the New York Academy of Sciences.

[36]  H Kesteloot,et al.  An Enquiry into the Role of Cobalt in the Heart Disease of Chronic Beer Drinkers , 1968, Circulation.

[37]  J. Kriss,et al.  THE HEMATOPOIETIC AND GOITROGENIC EFFECTS OF COBALTOUS CHLORIDE IN PATIENTS WITH SICKLE CELL ANEMIA , 1955, Pediatrics.

[38]  W. Carnes,et al.  Hypothyroidism and thyroid hyperplasia in patients treated with cobalt. , 1955, Journal of the American Medical Association.